All In Biotech

Drug Trial Radar · NCT04839367

Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER)

Positron Emission Tomography Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA: A Multi-Centre, Blinded Review, Dose Ranging Phase I Study

Last checked: Nov 20, 2026Latest source record: Jan 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Jul 13, 2021

Primary completion

Oct 19, 2022

Study completion Oct 19, 2022

Sponsor

Lead sponsor
Clarity Pharmaceuticals LtdIndustry
Sponsor type
Industry
First posted
Apr 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to determine the safety and tolerability of 64Cu-SARbisPSMA in participants with untreated, confirmed Prostate Cancer.

Conditions

  • Prostatic Neoplasms

Interventions

  • 64Cu-SAR-bisPSMADrug

    64Cu-SAR-bisPSMA

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of 64Cu-SAR-bisPSMA using Common Terminology Criteria for Adverse Events version 5Time frame: 11 weeks
  2. Efficacy of 64Cu-SAR-bisPSMA in the Detection of Primary Prostate Caner Compared to HistopathologyTime frame: 11 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Nepean Hospital

    Kingswood, New South Wales, Australia

  • St. Vincent's Hospital

    Sydney, New South Wales, Australia

  • GenesisCare CTA, SJOG Medical Clinic

    Murdoch, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.